<DOC>
	<DOCNO>NCT02510261</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy long-term dose ALN-TTR02 ( patisiran ) patient transthyretin ( TTR ) mediate amyloidosis ( ATTR ) .</brief_summary>
	<brief_title>The Study Investigational Drug , Patisiran ( ALN-TTR02 ) , Treatment Transthyretin ( TTR ) -Mediated Amyloidosis Patients Who Have Already Been Treated With ALN-TTR02 ( Patisiran )</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Have complete patisiran study ( i.e. , complete last efficacy visit parent study ) , opinion investigator , tolerate study drug Be willing able comply protocolrequired visit schedule visit requirement provide write informed consent Any new uncontrolled condition could make patient unsuitable participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RNAi therapeutic</keyword>
	<keyword>FAP</keyword>
	<keyword>Familial Amyloid Polyneuropathy</keyword>
	<keyword>TTR</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>Amyloidosis</keyword>
</DOC>